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Abstract
Context—Intensive treatments intended to sustain life are often used for patients with advanced
cystic fibrosis (CF). There are no guidelines for selecting patients whose survival and quality of
life may be enhanced by such treatments or for communication with patients and caregivers about
possible treatment outcomes.
Objectives—We aimed to describe caregivers’ perspectives on decision making for the use of
intensive treatments for patients with advanced CF lung disease.
Methods—We conducted semi-structured interviews with 36 caregivers of 36 patients who died
of CF about treatment preference discussions and solicited recommendations for improving
discussions.
Results—Twenty (56%) patients received intensive treatments during the last week of life.
Twenty-two (61%) caregivers reported ever having discussed intensive treatment preferences with
a physician, and 17 (77%) of these discussions were initiated during an acute illness. Only 14
(39%) of all patients participated. Caregivers expressed less certainty about consistency of
treatments with patient preferences when patients did not participate. Twenty-nine (81%)
caregivers endorsed first discussing treatment preferences during a period of medical stability.
Conclusions—Discussions about preferences for the use of intensive treatments for patients
with CF often take place during episodes of acute illness and may be delayed until patients
themselves are too ill to participate. Bereaved caregivers suggest first addressing intensive
treatment preferences during a stable period so that patient preferences are understood and
unwanted treatments are minimized.
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Introduction
The natural history of cystic fibrosis (CF) is a progressive decline in lung function over
time, with intermittent acute exacerbations and, for some, periods of accelerated decline.1
Although survival in CF is increasing over time,2 patients are cognizant of a shortened
lifespan for many years preceding death. Intensive treatments, such as noninvasive
ventilation or mechanical ventilation, which are intended to sustain life when used during
acute respiratory decompensation, are commonly used in patients with advanced CF lung
disease.3–5 Although these treatments were historically thought to have significant morbidity
and limited benefit,6–8 more recent literature supports consideration of these treatments on a
patient-to-patient basis, with particular attention to their use as a bridge to lung
transplantation.5,8–11 Without a firm evidence base or guidelines for selecting patients
whose survival and quality of life may be enhanced by such treatments, appropriately
informing patients of the risks and benefits of treatment options may be challenging.
Additionally, the availability of lung transplantation for advanced CF lung disease may
complicate patient-physician communication about treatment preferences.12
Investigations suggest that CF clinicians lack a framework for initiating effective
communication with patients and their caregivers regarding preferences for the use of
intensive treatments.13,14 Advance care planning to foster alignment of medical care with
individual patients’ goals and preferences may not be routinely included in the care of
patients with advanced CF13 despite recommendations for its early incorporation into
routine CF care.14,15 Little is known, though, about actual practice and whether it
corresponds to these recommendations.
Our goal in the present study was to better understand caregivers’ perspectives on decision
making for the use of intensive treatments for patients with advanced CF lung disease. We
interviewed caregivers of patients who died of complications of CF to characterize the
timing of discussions about the use of intensive treatments and the frequency of patient
participation. We assessed the outcomes of these discussions by inquiring whether
treatments received were consistent with stated preferences. We also elicited
recommendations for improving discussions about intensive treatment preferences.
Methods
Subjects
We identified caregivers of all patients with CF who died of complications of CF or from
bronchiolitis obliterans syndrome after lung transplantation between 1996 and 2006. We
included only caregivers of patients who received their primary CF and/or lung transplant-
related care at our institution. We mailed letters to 54 caregivers with current contact
information requesting participation in a study about treatment preferences and end-of-life
care and asked them to return postage-paid letters if they wished not to be contacted by
telephone. We did not contact caregivers or conduct interviews within 60 days of major
holidays, patients’ birthdays, or anniversaries of patients’ deaths. Of 54 eligible caregivers,
five could not be reached by telephone to follow up the request for participation. Forty-nine
were contacted, and 39 (80%) agreed to participate. Of the 10 who declined, seven provided
no explanation, two cited sadness related to the patient’s death, and one felt uncomfortable
participating because of the declining health of another family member with CF. Thirty-six
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caregivers, representing 36 caregiver-patient pairs, answered questions about treatment
preference discussions sufficiently for analysis.
Interviews
Participants completed a semi-structured interview about the experiences of corresponding
patients who died of complications of CF. We adapted questions about end-of-life care from
existing bereavement questionnaires16–18 and developed a series of closed-ended questions
addressing whether and when discussions about intensive treatment preferences occurred,
whether or not patients participated in these discussions, and whether patient preferences
were upheld. Participants were invited to expand on responses to closed-ended questions.
This qualitative approach was chosen because of the paucity of data about treatment
decision making in CF, a small potential subject pool, and our goal of exploring concepts
that might inform the development of future prospective studies about treatment decision
making and advance care planning in CF.
The interview script was reviewed by all investigators, approved by our institutional review
board, and then pilot tested with three care-givers (two parents and one sibling) of patients
who died of CF. One investigator (E. D.) conducted all interviews by telephone after
obtaining verbal informed consent from participants. Audiotaped interviews were
professionally transcribed. Interviews were designed to last 60 minutes; average length was
54 minutes (range 30–90 minutes). We assessed transcripts for consistency of information
reported by care-givers with patient information contained in our CF database and medical
records.
Data Analysis
Summary statistics were used to analyze results to closed-ended questions about timing of
treatment preference discussions, patient participation in discussions, and consistency of
treatments with patient preferences. We categorized responses about timing of first
discussions about intensive treatment preferences based on whether these discussions took
place during a stable period, including routine clinic visits and during outpatient discussions
about referral for lung transplantation, or during acute illness, such as during hospitalization
for a severe respiratory exacerbation or when death was felt to be imminent. Differences in
categorical variables and trends were compared using χ2 for larger samples and Fisher’s
exact test for smaller samples. Missing variables were excluded from the analysis. Expanded
responses to closed-ended questions were reviewed for suggestions about improving
treatment preference discussions, and representative quotes were selected for inclusion in
this presentation of the data.
Results
Caregiver and Patient Characteristics
Caregiver and patient characteristics are summarized in Table 1. Most caregivers
interviewed identified themselves as the primary caregiver to their corresponding patients,
and those who did not, stated that the patient was independent with regard to disease
management. Patients, overall, were seriously ill; 81% used oxygen chronically, many had
limited functional capacity and required frequent hospitalizations for respiratory illnesses,
and most died of respiratory failure. Most met medical criteria for referral for lung
transplantation,19,20 and 70% were either awaiting or had undergone transplantation. All
lung transplant recipients had developed severe bronchiolitis obliterans syndrome, with lung
function in the range where transplanting CF lungs might be considered. A small minority
(8%) was offered a transplant and was declined. Eighty-one percent of patients died in the
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hospital, and 47% of deaths occurred in intensive care units. Patient deaths occurred an
average of 6.7 years (range 1.8–10.9 years) before the interview.
Given the sensitive nature of the topic and the decision to conduct interviews by telephone,
we asked the first 12 caregivers whether or not they considered the interview to be an
emotional burden and whether they would recommend participation to other bereaved
caregivers. Eleven of 12 felt the interview was not an emotional burden, with one stating
that it was somewhat of a burden; all 12 said that they would recommend participation in the
study to other caregivers.
Participants in Discussions About Intensive Treatment Preferences
Features of discussions about intensive treatment preferences between patients, physicians,
and caregivers are summarized in Table 2. Twenty-two (61%) caregivers reported that a
discussion with a physician about intensive treatment preferences ever occurred; 14 (39%)
of these discussions included the patient, with the remaining taking place between care-giver
and physician. Only half of the caregivers reported that the patient had ever discussed
intensive treatment preferences directly with them before a discussion taking place with a
physician. Patients who had never discussed treatment preferences with a caregiver were
less likely to participate directly in discussions with physicians (17%) than those who had
(83%; P < 0.01); rather, these conversations were limited to physicians and caregivers.
Inquiry about other advance care planning revealed that only 37% of adult patients had
designated a surrogate decision maker, and one-third had advance directives.
Timing of Discussions About Intensive Treatment Preferences
A large proportion (77%) of discussions about intensive treatment preferences were initiated
during acute illness, either while hospitalized for a severe respiratory exacerbation or when
death was felt to be imminent. In contrast, 64% of caregivers recommended starting these
discussions during stable periods, and an additional 17% felt this was ideal, but that patient
and family factors may influence actual timing of discussions. Trends toward discussions
occurring during acute illness rather than during stable periods were identified for children,
for patients who did not discuss intensive treatment preferences with a care-giver, for lung
transplant candidates, and for patients who did not meet lung function criteria for transplant
referral. Most caregivers (91%) felt that discussions about intensive treatment preferences
should be initiated by physicians.
Consistency of Treatments with Patient Preferences
A minority of patients themselves participated in discussions with physicians about intensive
treatment preferences, most often, because, at the time of the discussion, the patient had
severe illness with altered level of consciousness or sedation for mechanical ventilation.
Thirteen of the 14 (93%) caregivers of patients who participated in treatment preference
discussions felt that the patient understood the reason for and content of the discussion very
well and that 11 (79%) definitely did not receive unwanted treatments. For the eight patients
who did not participate in the discussion, only two (25%) caregivers felt certain that no
unwanted treatments were administered (P = 0.14).
Overall, 20 (55%) caregivers felt certain that no unwanted treatments were administered, 14
(39%) were uncertain, and two (6%) reported knowing that the patient received unwanted
treatments. Fewer caregivers felt confident that no unwanted treatments were administered
when discussions occurred during acute illness vs. during stable periods (20% vs. 47%, P =
0.36) and when no discussion occurred (41% vs. 84%; P = 0.03). Of the 10 patients who
never discussed treatment preferences with a physician and whose care-givers were
uncertain about their receipt of unwanted treatments, six were sedated for mechanical
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ventilation, and the remaining four were unable to communicate effectively because of
respiratory distress and altered mental status. Both caregivers who knew that their
corresponding patients received unwanted treatments reported feeling pressure from
physicians to pursue these treatments, with one stating: “[Physician] looked at mechanical
ventilation like the magical thing.”
Caregiver Recommendations for Discussions About Intensive Treatment Preferences
Most of the caregivers endorsed initiating discussions about intensive treatment preferences
during a period of stability. All who felt that appropriate timing depended on patient
characteristics favored discussions during stable periods, but some pointed out that this may
not always be possible because of unanticipated life-threatening illness. Others noted that
some patients and caregivers are not well-equipped to participate in such discussions
because of lack of understanding, fear of death, or denial of the severity of illness or of
disease prognosis. One caregiver commented, “You can’t wait until somebody’s on death’s
door. And you can’t talk to them today and expect a decision.” Another caregiver who noted
the importance of patient preferences being known to all members of the medical team said,
“… So if certain decisions have already been discussed … and it was done deliberately and
wasn’t something that had to be quickly started on the spot, … [patient] could really talk it
through and come to that decision.”
Many caregivers offered suggestions for improving communication or timing of treatment
preference discussions. Some suggested providing more information to patients and
caregivers about indications for and potential outcomes of intensive treatments. Of note,
nine caregivers mentioned knowing that outcomes of mechanical ventilation in CF are often
poor, but only four recalled hearing this from a physician, whereas the remaining five
received this information from other patients and caregivers. Some caregivers remarked that
addressing treatment preferences first during acute illness is not ideal; hospitalizations or
times of decline in health are appropriate times to readdress preferences. Many mentioned
that decisions are often affected by situational factors, with one caregiver of a patient with
whom no discussion occurred stating, “[Have these discussions] early instead of getting
close to when you might be depressed or desperate just because you’re facing dying.”
Most caregivers felt that patients should participate in discussions so as to enhance their
understanding of treatment decisions; delaying discussions until patients are too ill to
participate may put caregivers in an uncomfortable position and place patients at risk of
receiving unwanted treatments. One caregiver said, “… I wish that I had had time to talk to
him, but I didn’t. The doctor said we have to intubate him now or he is going to die. And I
hated that because it scared me. I am sure it scared him. And I had to make a decision very
quickly but I wanted to talk to his father, so I was running around trying to call him. And the
panic that you have because you need to make this decision quickly.” Another said, “… I
feel like maybe there should have been a discussion before she got so ill that she couldn’t
talk about it, so that we could have spoken with her about it so that the doctors would know.
Because I truly don’t think those doctors truly understood how she felt.”
Most caregivers felt that the primary CF physician should initiate discussions about
intensive treatment preferences. Three care-givers expressed anger about physicians not
initiating discussions, noting that these are difficult issues for patients and caregivers and
that by “opening the door,” as one caregiver stated, patients and caregivers can then help
guide the direction of discussions. Although many acknowledged the difficult nature of
these discussions, they also pointed out that patients and caregivers are aware that CF is life
limiting; thus, discussing treatment preferences is necessary and appropriate. One stated, “…
inevitably they [patients] are going to realize that this is a life-threatening disease …unless
they’re totally unable to talk about it or don’t comprehend, they are going to wonder, what’s
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my life going to be like? And I think picking up on those cues would be important as early
as possible.”
Discussion
As intensive treatments intended to sustain life are often used for patients with advanced CF
despite a lack of guidelines for selecting patients who may derive benefit or a framework for
communication with patients and care-givers about possible treatment outcomes, we sought
to understand caregivers’ perspectives on treatment decision making. We found that
discussions about preferences for the use of intensive treatments often take place during
acute illness and late in the disease course, and that patient participation may be affected by
the timing of these discussions. Discussions during acute illnesses rather than during stable
periods may be even more common for younger patients, those who await or have
undergone lung transplantation, and those who do not communicate about treatment
preferences with their caregivers independently of discussions with physicians. The
caregivers we interviewed endorsed discussing intensive treatment preferences during
periods of medical stability and readdressing preferences over time. The vast majority felt
that physicians, not patients or caregivers, should initiate discussions about treatment
preferences.
Medical care for patients with advanced CF lung disease often incorporates more intensive
treatments and preventive treatments than those used in the traditional model of palliative
care.14,21 Many factors likely influence the utilization of intensive treatments, including, but
not limited to, the availability of lung transplantation, the young age at death of many
patients, lifelong experience of frequent medical interventions, and the fact that many
patients with CF die in the hospital.3,22,23 The anticipated course is a gradual downward
trajectory in lung function, but episodes of acute illness and severe exacerbations from
which patients do not return to their previous state of health are difficult to predict, and a
terminal phase may be difficult to recognize for physicians, patients, and caregivers alike.
Although predictive models of survival and lung transplant outcomes in CF exist,24,25 their
appropriate application to clinical practice is uncertain. All of these factors may make the
appropriate timing of discussions about intensive treatment preferences difficult to
determine.
Incorporation of advance care planning into routine CF care is recommended,14,15 and
initiating discussions about intensive treatment preferences and other advance care planning
earlier and more systematically could allow patients to make more informed choices and
achieve better palliation of symptoms.26 Additionally, the care provided to patients with
advanced disease could be more consistent with patient and caregiver goals, with unwanted
treatments minimized and desired treatments offered when felt to be appropriate. Although
physicians who care for patients with CF may not routinely address the various aspects of
advance care planning, our study suggests that patients and caregivers want and expect
physicians to initiate discussions about the use of intensive treatments. Perhaps more
advance care planning would follow from a different strategy for communicating with
patients and caregivers.
For physicians to develop strategies for addressing these issues with patients and care-
givers, they must recognize that discussing treatment preferences with patients fosters
communication between patients and their caregivers and relieves some of the burden of
surrogate decision making often placed on caregivers.27 Physician practices for discussing
intensive treatment preferences with CF patients and their caregivers have not been
described, and there is no common framework for initiating effective communication with
patients and their caregivers regarding treatment preferences.
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There are a number of limitations to this study. First, this is a single-center study; hence, it
does not address practices at other CF-care centers. We only interviewed caregivers whose
corresponding patients died, and the views of caregivers of living patients may be different.
We asked caregivers to recall details of discussions that took place many years before the
interview. Because CF is a relatively uncommon disease, the only way to collect adequate
numbers of participants is to include patients over time. To assess accuracy of responses, we
compared recalled events with factual demographic and disease-specific information
previously abstracted from medical records and found concordance. Using caregivers as
surrogates for patients may misrepresent actual events or the feelings and opinions of
patients themselves, but as caregivers are closely involved in the care of many patients with
CF even into adulthood,28 including making complex medical decisions, their perspectives
are useful in addressing the study questions. Additionally, use of surrogates to study end-of-
life experiences29 and to inform advance care planning is the most feasible method to collect
data on patients’ experiences in the final moments of life.30
Despite these limitations, the findings of our study suggest a need for further exploration in
the areas of communicating about treatment preferences and advance care planning in CF.
Further studies of physician practices and prospective studies of patients and caregiver
experiences may help to provide a framework for such discussions. The impact of lung
transplant on treatment decision making also warrants further attention. Improving
communication about these important issues will allow for more concordance between
patient and care-giver goals and the care provided by physicians.
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Table 1
Caregiver and Patient Characteristics (n = 36 Caregiver-Patient Pairs)
Caregiver and Patient Characteristics Number (% of 36 Total Caregivers) Unless Otherwise Indicated
Caregiver characteristics
Median age in years (range) 57 (32–82)
Relationship with patient
 Parent 31 (86)
 Spouse 2 (6)
 Sibling 1 (3)
 Grandparent 1 (3)
 Friend 1 (3)
Female gender 32 (89)
Primary caregiver to patient 30 (83)
Patient characteristics
Median age at death in years (range) 23.7 (8–47)
Adult (age ≥18 years) 24 (67)
Frequency of hospitalizations during last 6 months of life
 Monthly 10 (28)
 Every other month 13 (36)
 Once or twice 12 (33)
 None 1 (3)
Level of function during last 6 months of life
 Very limited 11 (31)
 Somewhat limited 17 (47)
 Not very limited 5 (14)
 Not limited at all 3 (3)
Lung transplant status
 Awaiting transplant 6 (17)
 Underwent transplant 19 (53)
 Declined transplant 3 (8)
 Not referred for transplanta 8 (22)
Cause of death
 Respiratory failure 33 (92)
 Septicemia 3 (8)
Location of death
 Hospital—medical ward 12 (33)
 Hospital—intensive care unit 17 (47)
 Home 7 (19)
Intensive treatments used in the last week of life
 Mechanical ventilation 14 (39)
 Noninvasive ventilation 6 (17)
 Cardiopulmonary resuscitation attemptedb 4 (11)













Dellon et al. Page 10
a
Of those not referred for transplant, three did not meet medical criteria for referral. Of the five who did, three were not referred because of
difficulties with adherence to therapies and two because of medical contraindications to transplant.
b
All patients also were receiving mechanical ventilation.
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Table 2
Patient-Physician Discussions About Intensive Treatment Preferences and Other Advance Care Planning:
Caregiver Responses
Characteristic of Discussion or Issue Discussed n (%)
Patient discussed intensive treatment preferences with caregiver 18 (50)
Discussion with a physician about intensive treatment preferences occurred 22 (61)
Patient definitely participated in discussion with a physician 14 (39)
Timing of first discussion about intensive treatment preferences
 During a period of stability 5 (23)
 During an acute illness 17 (77)
Caregiver’s perception of ideal time for first discussion to take place
 During a period of stability 23 (64)
 During an acute illness 7 (19)
 Appropriate time depends on patient and caregiver characteristics 6 (17)
Caregiver’s perception of who should initiate discussions about intensive treatment preferences
 Primary CF physician 33 (91)
 Patient or family member 2 (6)
 Social worker 1 (3)
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